N-propargylglycine restores survival by preventing calcium oxalate stone formation, tubular injury, and kidney dysfunction in a lethal mouse model of primary hyperoxaluria type 2
doi.org/10.1016/j.kint.2026.02.024
#MedSky #NephSky #OpenAccess
📢 The FDA has approved the first ever treatment for FSGS, supported by the PARASOL initiative.
RaDaR contributed as an external validation cohort, highlighting the power of global collaboration & patient data.
📰: https://ow.ly/IJNH50YJXBB
#RareDisease #KidneyResearch #FSGS
#NephMadness 2026
Really enjoyed this year’s writeups.. thoughtful and high-yield 👏
There’s a clear shift in nephrology: from broad immunosuppression → more targeted therapies.
Still learning the ropes, but this was fun 🙂
Curious to see which direction the panel leans 👀
#NephMadnessNewbie
#NephMadness 2026: The PodCrawl
Featuring these podcasts:
- GN in Ten @isgd.bsky.social
- Global Kidney Care @theisn.org
- @freelyfiltered.bsky.social
- @febrilepodcast.com
- Kidney Commute @nkf-professionals.bsky.social
- @coreimpodcast.bsky.social
- Nephron Segment
bit.ly/NM26Podcrawl
⏰ Just a few hours left to submit your #NephMadness 2026 bracket!
The fun of #NephMadness is making your prediction on which team will become the 2026 Champion.
Already submitted one? Disagreed with the group?
Submit a back-up bracket: bit.ly/2DvWyou
Also see this study from India in @kireports.bsky.social
Is there somethung special about
targeted release $$$
vs
enteric coated $
budesonide?
bsky.app/profile/hswa...
#ISNWCN
Hi, I’m Sruthi, Nephrologist from Kerala, India.
I’m into clinical medicine, research, and lately curious about AI.
Outside work, I enjoy time with family, art, and real conversations.
Here to learn, connect, and grow 🙂
#Nephsky #Nephbluesky #Medsky